OBJECTIVE: To assess the efficacy of topical Tripterygium wilfordii (TW), a Chinese herbal therapy, in rheumatoid arthritis (RA). METHODS: A 6 week randomized double blind placebo controlled study of 61 patients with RA meeting American College of Rheumatology (ACR) criteria was conducted in China. The primary outcome was a modified ACR-20 response rate, analyzed by logistic regression analysis. RESULTS: The modified ACR-20 response rate differed significantly (topical TW 58% vs placebo 20%; p = 0.002). There was an 8.1-fold (95% CI 1.9-35.4) increase in the modified ACR-20 response for the TW compared to the placebo group, adjusted for age and erythrocyte sedimentation rate. CONCLUSION:Topical TW appears efficacious for the treatment of RA, but larger studies are needed.
RCT Entities:
OBJECTIVE: To assess the efficacy of topical Tripterygium wilfordii (TW), a Chinese herbal therapy, in rheumatoid arthritis (RA). METHODS: A 6 week randomized double blind placebo controlled study of 61 patients with RA meeting American College of Rheumatology (ACR) criteria was conducted in China. The primary outcome was a modified ACR-20 response rate, analyzed by logistic regression analysis. RESULTS: The modified ACR-20 response rate differed significantly (topical TW 58% vs placebo 20%; p = 0.002). There was an 8.1-fold (95% CI 1.9-35.4) increase in the modified ACR-20 response for the TW compared to the placebo group, adjusted for age and erythrocyte sedimentation rate. CONCLUSION: Topical TW appears efficacious for the treatment of RA, but larger studies are needed.
Authors: Ying-Hua Yang; Rajesh Rajaiah; David Y-W Lee; Zhongze Ma; Hua Yu; Harry H S Fong; Lixing Lao; Brian M Berman; Kamal D Moudgil Journal: Evid Based Complement Alternat Med Date: 2010-10-19 Impact factor: 2.629
Authors: Shivaprasad H Venkatesha; Rajesh Rajaiah; Brian M Berman; Kamal D Moudgil Journal: Evid Based Complement Alternat Med Date: 2010-12-22 Impact factor: 2.629
Authors: Siddaraju M Nanjundaiah; David Y-W Lee; Brian M Berman; Kamal D Moudgil Journal: Evid Based Complement Alternat Med Date: 2013-05-16 Impact factor: 2.629